RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
磷脂酰肌醇蛋白聚糖 3：肝细胞癌治疗的新兴且有前景的靶点
英文原题：Glypican-3: A Novel and Promising Target for the Treatment of Hepatocellular Carcinoma.
查看英文原题
Glypican-3: A Novel and Promising Target for the Treatment of Hepatocellular Carcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
聚糖蛋白3（GPC3）是一种膜相关蛋白聚糖，在肝细胞癌（HCC）中特异性上调，而在正常肝组织中很少表达或不表达，因此是HCC理想的诊断和治疗靶点。目前正在开展多项GPC3相关临床试验，近期也出现了若干创新的GPC3靶向治疗方法并取得令人鼓舞的结果，包括GPC3疫苗、抗GPC3免疫毒素、联合免疫检查点阻断（ICB），以及嵌合抗原受体（CAR）T细胞或NK细胞。本文综述GPC3在HCC诊断和预后评估中的价值及其相关信号通路，重点介绍GPC3靶向HCC治疗，并展望未来基于GPC3的治疗策略。
展开英文摘要原文
Glypican-3 (GPC3) is a membrane-associated proteoglycan that is specifically up-regulated in hepatocellular carcinoma (HCC) although rarely or not expressed in normal liver tissues, making it a perfect diagnostic and treatment target for HCC. Several GPC3-based clinical trials are ongoing and recently several innovative GPC3-targeted therapeutic methods have emerged with exciting results, including GPC3 vaccine, anti-GPC3 immunotoxin, combined therapy with immune checkpoint blockades (ICBs), and chimeric antigen receptor (CAR) T or NK cells.
Here, we review the value of GPC3 in the diagnosis and prognosis of HCC, together with its signaling pathways, with a specific focus on GPC3-targeted treatments of HCC and some prospects for the future GPC3-based therapeutic strategies in HCC.
论文信息
- 作者
- Zheng X、Liu X、Lei Y、Wang G、Liu M
- 单位
- Department of Abdominal Oncology, West China Hospital, Sichuan University, Chengdu, China.China
- 文献类型
- 综述
- 期刊
- Frontiers in oncology2022
- 原文标识
- PubMed 35251989 · DOI 10.3389/fonc.2022.824208
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →